SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2602Here is one way to think about this situation. Instead of only trying to figurekenhott-11/2/2010
2601Today’s CC changes nothing, IMO. That Teva’s application is being examined by OBDewDiligence_on_SI-11/2/2010
2600Dew, I've been watching the back and forth on iHub about TEVA's "cJeffry K. Smith-11/2/2010
2599I did have to chuckle though, I guess teva being greatly disappoointed this yearmopgcw111/2/2010
2598My first reaction was that it 'might' be a buying opportunity, however, Arthur Radley-11/2/2010
2597personally, I think it starts to get interesting below $14 for adding to the posmopgcw111/2/2010
2596Yes. But the question is whether mnta's technology will give them any sort orkrw211/2/2010
2595Delete that - non compos mentistom pope-11/2/2010
2594The reason for the swoon is what was said on Teva’s CC this morning: siliconinvDewDiligence_on_SI111/2/2010
2593Stock just hit a downward slope.......volume already at daily norm.......anyone Arthur Radley-11/2/2010
2592more importantly, those are the clues to future pipeline progressions..mopgcw111/2/2010
2591finance.yahoo.com Small amounts of funding......but better than a 'sharp stArthur Radley111/2/2010
2590cc Seekingalpha: Momenta Pharmaceuticals, Inc. (MNTA) Q3 2010 Earnings Call Tranmopgcw111/2/2010
2589I trust Eyal Desheh. If he says Teva's product is different from Lupin'sidos-11/2/2010
2588So TEVA's product is not TEVA's product, eh? Can you trust anything theJeffry K. Smith-11/2/2010
2587Just got an indirect (from an analyst who met Teva's CFO) reply. Before askiidos-11/2/2010
2586Thanks, Cary. I posted AMGN’s PR on iHub with some annotations and links to relaDewDiligence_on_SI111/2/2010
2585similar vs full characterization?tom pope111/1/2010
2584I'd think the Amgen comments might be helpful for Momenta.rkrw111/1/2010
2583I smell a hidden agenda in there. BTW, for an example of an incident that shoultom pope111/1/2010
2582Please ignore the ‘ReadMeFirst’ link in my previous post and use this one insteaDewDiligence_on_SI111/1/2010
2581finance.yahoo.comArthur Radley111/1/2010
2580Updated again for 3Q10 financials (EPS=$0.71): siliconinvestor.comDewDiligence_on_SI111/1/2010
2579MNTA ‘ReadMeFirst’ updated: siliconinvestor.com <i><u>Lovenox</DewDiligence_on_SI-10/31/2010
2578"breakouts" are often the road to perdition with me, but this looks entom pope-10/28/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News